Zhengye Biotechnology Holding Limited
ZYBT Healthcare Drug Manufacturers Specialty & Generic
Zhengye Biotechnology Holding Limited’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, down 34.8% from fiscal 2024.
Follow ZYBT
Zhengye Biotechnology Holding Limited (ZYBT) Altman Z-score
Zhengye Biotechnology Holding Limited's Altman Z-score for fiscal 2025 is 1.47, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 1.47 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.04 | — | 0.05 | |
| Retained earnings / total assets | (0.05) | — | −0.07 | |
| EBIT / total assets | (0.16) | — | −0.53 | |
| Market value of equity / total liabilities | 2.93 | — | 1.76 | |
| Sales / total assets | 0.27 | — | 0.27 | |
| Altman Z-score | Distress zone | 1.47 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Grey zone | 1.49 | ||
Z and Z″ put Zhengye Biotechnology Holding Limited in different zones: distress zone by Z, grey zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ZYBT Zhengye Biotechnology Holding Limited | 1.5× |
| INCR InterCure Ltd. compare | 0.1× |
| CPHI China Pharma Holdings, Inc. compare | −2.2× |
| SCYX SCYNEXIS, Inc. compare | −7.0× |
| RMTI Rockwell Medical, Inc. compare | −7.4× |
| IXHL Incannex Healthcare Inc. compare | −13.2× |
| TLPH Talphera, Inc. compare | −20.7× |
| CTOR Citius Oncology, Inc. compare | — |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets